Didanosine (ddI, Videx)

For additional information see Drugs@FDA:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

Formulations

Videx pediatric powder for oral solution: reconstituted 10 mg/ml

Videx enteric-coated (EC) delayed-release capsules (EC beadlets): 125 mg, 200 mg, 250 mg, and 400 mg

Generic ddI delayed-release capsules: 200 mg, 250 mg, and 400 mg

Dosing Recommendations

Neonate/infant dose (2 weeks to <3 months of age):
50 mg/m^2 of body surface area every 12 hours.

(Manufacturer recommends 100 mg/m^2 of body surface area every 12 hours in this age range. Panel members interpret pharmacokinetic [PK] data as suggesting potential increased toxicity at that dose in this age group and many would use 50 mg/m^2 of body surface area every 12 hours.)

Infant dose (>3 months to 8 months of age):
100 mg/m^2 of body surface area every 12 hours.

Pediatric dose of oral solution (>8 months of age):
120 mg/m^2 of body surface area every 12 hours. (Dose range: 90–150 mg/m^2 of body surface area every 12 hours, maximum dose 200 mg/dose twice daily.)

Pediatric dose of Videx EC or generic capsules (ages 6–18 years and body weight ≥20 kg):

Body Weight (kg)	Dose (mg)
20 kg to <25 kg	200 mg once daily
25 kg to <60 kg	250 mg once daily
≥60 kg	400 mg once daily

In treatment-naive children 3–21 years of age, 240 mg/m^2 of body surface area once daily (oral solution or capsules) has been used with effective viral suppression.

Selected Adverse Events

- Peripheral neuropathy
- Electrolyte abnormalities
- Diarrhea, abdominal pain, nausea, and vomiting
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported in adults. (The risk is increased when ddI is used in combination with stavudine [d4T].)
- Pancreatitis (less common in children than in adults, more common in adults when ddI is used in combination with tenofovir [TDF] or d4T)
- Potential association with noncirrhotic portal hypertension
- Retinal changes, optic neuritis
- Insulin resistance/diabetes mellitus

Special Instructions

- Because food decreases absorption of ddI, it is generally recommended to administer ddI on an empty stomach (30 minutes before or 2 hours after a meal). To improve adherence, some practitioners administer ddI without regard to timing of meals (see Pediatric Use).
- ddI oral solution contains antacids that may interfere with the absorption of other medications.
- Shake ddI oral solution well before use. Keep refrigerated; admixture is stable for 30 days.

Metabolism

- Renal excretion 50%.

Adolescent/adult dose:

Body Weight (kg)	Dose (mg)
<60 kg	250 mg once daily
≥60 kg	400 mg once daily

ddI in combination with TDF:
This combination should be avoided if possible because of enhanced ddI toxicity.

Pediatric/adolescent dose of ddI when combined with TDF:
There is no data on this combination in children or adolescents <18 years of age, but decrease in ddI dose is recommended as in adults.

Adult dose of ddI when combined with TDF:

Body Weight (kg)	Dose (mg)
<60 kg (limited data in adults)	200 mg once daily
≥60 kg	250 mg once daily

- **Dosing of ddI in patients with renal insufficiency:** Decreased dosage should be used in patients with impaired renal function. Consult manufacturer's prescribing information for adjustment of dosage in accordance with creatinine clearance (CrCl).

Drug Interactions (See also the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.)***:***

- *Absorption:* The presence of antacids in the didanosine suspension has the potential to decrease the absorption of a number of medications if given at the same time as didanosine. Many of these interactions can be avoided by timing doses to avoid giving other medications concurrently with didanosine suspension.
- *Mechanism unknown:* Didanosine serum concentrations are increased when didanosine is coadministered with tenofovir and this combination should be avoided if possible.
- *Renal elimination:* Drugs that decrease renal function could decrease clearance of didanosine.
- *Enhanced toxicity:* Didanosine mitochondrial toxicity is enhanced by ribavirin.
- *Overlapping toxicities:* The risk of pancreatitis and peripheral neuropathy is increased with use of some nucleoside reverse transcriptase inhibitors (NRTIs) (such as stavudine). The combination of stavudine and didanosine is not recommended (unless the benefits clearly outweigh the risks) because of overlapping toxicities and reports of serious, even fatal, cases of lactic acidosis with hepatic steatosis with or without pancreatitis in pregnant women.

Major Toxicities:

- *More common:* Diarrhea, abdominal pain, nausea, and vomiting.
- *Less common (more severe):* Peripheral neuropathy, electrolyte abnormalities, and hyperuricemia. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported.

Pancreatitis (less common in children than in adults, more common in adults when didanosine is used in combination with tenofovir), increased liver enzymes, and retinal depigmentation and optic neuritis have been reported. The combination of stavudine with didanosine may result in enhanced toxicity (increased risk of fatal and nonfatal cases of lactic acidosis or pancreatitis); this combination should not be used unless the potential benefit clearly outweighs the potential risk.

- *Rare:* Noncirrhotic portal hypertension, with increased transaminases, increased alkaline phosphatase, and thrombocytopenia, has been associated with long-term didanosine use in adults[1-3]. In adults, use of didanosine may be associated with increased risk of myocardial infarction[4-5].

Resistance: The International Antiviral Society-USA (IAS-USA) maintains a list of updated resistance mutations (see http://www.iasusa.org/resistance_mutations/index.html) and the Stanford University HIV Drug Resistance Database offers a discussion of each mutation (see http://hivdb.stanford.edu/pages/GRIP/ddI.html).

Pediatric Use: Didanosine is Food and Drug Administration (FDA) approved for use in children as part of a dual-NRTI backbone in combination antiretroviral therapy (cART).

Recommended doses of didanosine oral solution in children have traditionally been 90–150 mg per meter^2 body surface area per dose twice daily. Doses higher than 180 mg per meter^2 body surface area twice daily are associated with increased toxicity[6]. In a simulation based on didanosine concentration data from 16 children, a dose of 90 mg per meter^2 body surface area twice daily was predicted to result in adequate drug exposure in only 57% of pediatric patients, compared with a predicted 88% of patients at a dose of 120 mg per meter^2 body surface area twice daily[7], which is the currently recommended dose for children from 8 months to 3 years of age.

For infants from 2 weeks to 8 months of age, the FDA recommends 100 mg per meter^2 body surface area per dose twice daily, increasing to 120 mg per meter^2 body surface area per dose twice daily at age 8 months. However, two small studies suggest that higher areas under the curve (AUCs) are seen in infants <6 weeks of age and that a dose of 100 mg per meter^2 body surface area per day (either as 50 mg per meter^2 body surface area per dose twice daily or 100 mg per meter^2 body surface area once daily) in infants <6 weeks of age achieves AUCs consistent with those of higher doses in older children[8-9]. Therefore, because these PK differences in younger infants (2 weeks to 3 months of age) compared with older children raise concern for increased toxicity in that age group, the Panel recommends a dose of 50 mg per meter^2 of body surface area twice daily for infants younger than 3 months.

A once-daily dosing regimen may be preferable to promote adherence, and multiple studies support the favorable PKs and efficacy of once-daily dosing. In a study of 10 children from 4 to 10 years of age, EC didanosine (Videx EC) administered as a single dose of 240 mg per meter^2 body surface area once daily was shown to have similar plasma AUC (although lower peak plasma concentrations) compared with the equivalent dose of buffered didanosine[8]. The resultant intracellular (active) drug concentrations are unknown. In 24 children with HIV infection, didanosine oral solution at a dose of 180 mg per meter^2 body surface area once daily was compared with 90 mg per meter^2 body surface area twice daily, and the AUC was actually higher in the once-daily group than in the twice-daily group[10]. In PACTG 1021 long-term virologic suppression with a once-daily regimen of efavirenz, emtricitabine, and didanosine (oral solution and EC beadlet capsules) was reported in 37 treatment-naive children 3 to 21 years of age[11]. The didanosine dose used in that study was 240 mg/meter^2/dose once daily, and PK analysis showed no dose changes were needed to reach PK targets[11]. A European trial of once-daily combination therapy that included didanosine at a dose of 200–240 mg per meter^2 body surface area in 36 children 3 to 11 years of age demonstrated safety and efficacy with up to 96 weeks of follow-up data[12]. In 53 children with ad-

vanced symptomatic HIV infection, once- versus twice-daily didanosine at a dose of 270 mg per meter^2 body surface area per day showed no difference in surrogate marker or clinical endpoints, except that weight gain was less in the children given once-daily therapy[13].

Although the prescribing information recommends taking didanosine on an empty stomach, this is impractical for infants who must be fed frequently and may decrease medication adherence by increasing regimen complexity. A comparison showed that regardless of whether didanosine oral solution was given to children with or without food systemic exposure was similar; however, absorption of didanosine administered with food was slower and more prolonged[14]. To improve adherence, some practitioners administer didanosine without regard to timing of meals. Studies in adults have suggested didanosine can be given without regard to food[15-16]. A European study dosed didanosine oral solution as part of a four-drug regimen either 1 hour before or 1 hour after meals, but allowed the extended-release formulation to be given without food restriction, and showed good virologic outcome with up to 96 weeks of follow-up[12].

References

1. Merchante N, Perez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. *Antivir Ther.* 2010;15(5):753-763.
2. Young J, Klein MB, Ledergerber B. Noncirrhotic portal hypertension and didanosine: a re-analysis. *Clin Infect Dis.* 2011;52(1):154-155.
3. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis.* 2009;49(4):626-635.
4. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet.* 2008;371(9622):1417-1426.
5. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis.* 2010;201(3):318-330.
6. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. *N Engl J Med.* 1991;324(3):137-144.
7. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. *Antimicrob Agents Chemother.* 2000;44(4):1029-1034.
8. King JR, Nachman S, Yogev R, et al. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. *Antivir Ther.* 2002;7(4):267-270.
9. Kovacs A, Cowles MK, Britto P, et al. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. *Pediatr Infect Dis J.* 2005;24(6):503-509.
10. Abreu T, Plaisance K, Rexroad V, et al. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother.* 2000;44(5):1375-1376.
11. McKinney RE Jr, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. *Pediatrics.* 2007;120(2):e416-423.
12. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. *Pediatrics.* 2007;119(3):e705-715.

13. Marchisio P, Principi N, Gabiano C, et al. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine. *Antivir Ther.* 1997;2(1):47-55.

14. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. *AIDS Res Hum Retroviruses.* 2000;16(5):415-421.

15. Sanchez-Conde M, Palacios R, Sanz J, et al. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. *AIDS Res Hum Retroviruses.* 2007;23(10):1237-1241.

16. Hernandez-Novoa B, Antela A, Gutierrez C, et al. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study. *HIV Med.* 2008;9(4):187-191.